Top

Tip

Swipe om te navigeren naar een ander artikel

Gepubliceerd in:

01-11-2007 | Original Paper

Relevance of Donepezil in Enhancing Learning and Memory in Special Populations: A Review of the Literature

Auteurs: J. Helen Yoo, Maria G. Valdovinos, Dean C. Williams

Gepubliceerd in: Journal of Autism and Developmental Disorders | Uitgave 10/2007

Abstract

This review discusses the laboratory and clinical research supporting the rationale for the efficacy of donepezil (Aricept® USA) in enhancing cognition in autism, Alzheimer disease, Down syndrome, traumatic brain injury, Attention Deficit Hyperactivity Disorder (ADHD), and schizophrenia. While preliminary animal models have shown effective, human studies exclusive of Alzheimer disease are sparse. Although attention and memory are unlikely a sole operation of the cholinergic system, evidence indicates a promising direction for further examination of this hypothesis in autism. Studies that examine changes in operationally defined behaviors and reliable and valid measure of changes in attention and memory are needed.

vorige artikel Impact of SMART Board Technology: An Investigation of Sight Word Reading and Observational Learning

volgende artikel Access to Care for Autism-Related Services

American Psychiatric Association (2000). Diagnostic and statistical manual of mental disorders text revision. Washington, DC: Author.

Anderson R., & Higgins, G. A. (1997). Absence of central cholinergic deficits in ApoE knockout mice. Psychopharmacology, 132, 135–144. PubMed

Barnes, C. A., Meltzer, J., Houston, F., Orr, G., McGann, K., & Wenk, G. L. (2000). Chronic treatment of old rats with donepezil or galantamine, effects on memory, hippocampal plasticity and nicotinic receptors. Neuroscience 99, 17–23. PubMed

Bauman, M. L., & Kemper, T. L. (1994). Neuroanatomic observations of the brain in autism. In M. L. Bauman, & T. L. Kemper. (Eds.), The neurobiology of autism (pp. 119–145). Baltimore, MD: Johns Hopkins University Press.

Berger-Sweeney, J., & Hohmann, C. F. (1997). Behavioral consequences of abnormal cortical development, insights into developmental disabilities. Behavior and Brain Research, 86, 121–142.

Bourgeois, J. A., Bahadur, N., & Minjares, S. (2002). Donepezil for cognitive deficits following traumatic brain injury: A case report. Journal of Neuropsychiatry Clinical Neuroscience, 14, 463–464.

Braida, D., Paladini, E., Griffini, P., Lamperti, M., Colibretti, L., & Sala, M. (1998). Long-lasting antiamnesic effect of a novel anticholinesterase inhibitor (MF 268). Pharmacology, Biochemistry, and Behavior, 59, 897–901. PubMed

Buccafusco, J. J., Jackson, W. J., Stone, J. D., & Terry, A. V. (2003). Sex dimorphisms in the cognitive-enhancing action of the Alzheimer’s drug donepezil in aged rhesus monkeys. Neuropharmacology, 44, 381–389. PubMed

Buchanan, R. W., Summerfelt, A., Tek, C., & Gold, J. (2002). An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. Schizophrenia Research, 59, 29–33.

Bullock, R., & Dengiz, A. (2005). Cognitive performance in patients with Alzheimer’s disease receiving cholinesterase inhibitors for up to 5 years. International Journal of Clinical Practice, 59, 817–822. PubMed

Carr, E. G., & Durand, V. M. (1985). Reducing behavior problems through functional communication training. Journal of Applied Behavior Analysis, 18, 111–126. PubMed

Chez, M. G., Aimonovitch, M. C., Buchanan, M. S., Mrazek, S. R., & Tremb, R. J. (2004). Treating autistic spectrum disorders in children: Utility of the cholinesterase inhibitor rivastigmine tartrate. Journal of Child Neurology, 19, 165–169.

Chez, M. G., Buchanan, T. M., Becker, M., Kessler, J., Aimonovitch, M. C., & Mrazek, S. R. (2003). Donepezil hydrochloride: A double-blind study in autistic children. Journal of Pediatric Neurology, 1, 83–88.

Conners, C. K., Levin, E. D., Sparrow, E., Hinton, S. C., Erhardt, D., Meck, W. H., et al. (1996). Nicotine and attention in adult attention deficit hyperactivity disorder (ADHD). Psychopharmacology Bulletin, 32, 67–73. PubMed

Cooper J. R., Bloom F. E., & Roth R. H. (1996). The biochemical basis of neuropharmacology (pp. 190–219). New York: Oxford University Press.

Court, J. A., Martin-Ruiz, C., Graham, A., & Perry, E. (2000). Nicotinic receptor in human brain: Topography and pathology. Journal of Chemical Neuroanatomy, 20, 281–298. PubMed

Coyle, J. T., Price, D. L., & de Long, M. R. (1983). Alzheimer’s disease: A disorder of cortical cholinergic innervation. Science, 219, 1184–1190. PubMed

Csernansky, J. G., Martin, M., Shah, R., Bertchume, A., Colvin, J., & Dong, H. (2005). Cholinesterase inhibitors ameliorate behavioral deficits induced by MK-801 in mice. Neuropsychopharmcology, 8, [Epub ahead of print]

Davis, R. E., Doyle, P. D., Carroll, R. T., Emmerling, M. R., & Jaen, J. (1995). Cholinergic therapies for Alzheimer’s disease. Arzneimittelforschung Drug Research 45, 425–431.

Davis, P., & Maloney, A. J. (1976). Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet, 2, 1403.

Dong, H., Csernansky, C. A., Martin, M. V., Bertchume, A., Vallera, D., & Csernansky, J. G. (2005). Acetylcholinesterase inhibitors ameliorate behavioral deficits in the Tg2576 mouse model of Alzheimer’s disease. Psychopharmacology, 19, [E-pub ahead of print]

Ellis, C. R., Singh, N. N., & Ruane, A. L. (1999). Nutritional, dietary, and hormonal treatments for individuals with mental retardation and developmental disabilities. Mental Retardation and Developmental Disabilities Research Reviews, 5, 335–341.

Erickson, S. K., Schwarzkopf, S. B., Palumbo, D., Badgley-Fleeman, J., Smirnow, A. M., & Light G. A. (2005). Efficacy and tolerability of low-dose donepezil in schizophrenia. Clinical Neuropharmacology, 28, 179–184. PubMed

Foldi, N. S., White, R. E. C., & Schaefer, L. A. (2005). Detecting effects of donepezil on visual selective attention using signal detection parameters in Alzheimer’s disease. International Journal of Geriatric Psychiatry, 20, 485–488. PubMed

Food and Drug Administration, Aricept (donepezil hydrochloride tablets). Retrieved August 2003, from http,//www.fda.gov/cder/foi/label/2001/20690s16lbl.pdf, 2000, December.

Freudenreich, O., Herz, L., Deckersbach, T., Evins, A. E., Henderson, D. C., Cather. C., et al. (2005). Added donepezil for stable schizophrenia: A double-blind, placebo-controlled trial. Psychopharmacology, 19, [E-pub ahead of print]

Frick, K. M., Stearns, N. A., Pan, J. Y., & Berger-Sweeney, J. (2003). Effects of environmental enrichment on spatial memory and neurochemistry in middle-aged mice. Learning and Memory, 10, 187–198. PubMed

Friedman, J. I., Adler, D. N., Howanitz, E., Harvey, P. D., Brenner, G., Temporini, H., et al. (2002). A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biological Psychiatry 51, 349–357. PubMed

Giacobini, E. (1993). Pharmacotherapy of Alzheimer’s disease: New drugs and novel strategies. Progress in Brain Research, 98, 447–454. PubMedCrossRef

Graham, A. J, Martin-Ruiz, C. M., Teaktong, T., Ray, M. A., & Court, J. A. (2002). Human brain nicotinic receptors, their distribution and participation in neuropsychiatric disorders. Current Drug Targets. CNS and Neurological Disorders, 1, 387–397. PubMed

Hardan, A. Y., & Handen, B. L. (2002). A retrospective open trial of adjunctive donepezil in children and adolescents with autistic disorder. Journal of Child and Adolescent Psychopharmacology, 12, 237–241. PubMed

Harris, N. S., Courchesne, E., Townsend, J., Carper, R. A., & Lord, C. (1999). Neuroanatomic contributions to slowed orienting of attention in children with autism. Cognitive Brain Research, 8, 61–71. PubMed

Hashimoto, M., Kazui, H., Matsumoto, K., Nakano, Y., Yasuda, M., & Mori, E. (2005). Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer’s disease? American Journal of Psychiatry, 162, 676–682. PubMed

Hayes, R. L, Lyeth, B. G., & Jenkins, L. W. (1989). Neurochemical mechanisms of mild and moderate head injury: Implications for treatment. In H. A. Levin, H. M. Eisenberg, & A. L. Benton (Eds.), Mild head injury (pp. 54–59). New York: Oxford University Press.

Heller, J. H., Spiridigliozzi, G. A., Doraiswamy, P. M., Sullivan, J. A., Crissman, B. G., & Kishnani, P. S. (2004). Donepezil effects on language in children with Down syndrome: Results of the first 22-week pilot clinical trial. American Journal of Medical Genetics, 130A, 325–326. PubMed

Heller, J. H., Spiridigliozzi, G. A, Sullivan, J. A., Doraiswamy, P. M., Krishnan, R. R., & Kishnani, P. S. (2003). Donepezil for the treatment of language deficits in adults with Down syndrome: A preliminary 24-week open trial. American Journal of Medical Genetics, 116A, 111–116. PubMed

Hertzman, M. (2003). Galantamine in the treatment of adult autism: A report of three clinical cases. International Journal of Psychiatry in Medicine 33, 395–398. PubMed

Hohmann, C. F., & Berger-Sweeney, J. (1998). Cholinergic regulation of cortical development and plasticity: New twists to an old story. Perspectives on Developmental Neurobiology, 5, 401–425. PubMed

Hoopes, S. P. (1999). Donepezil for Tourette’s disorder and ADHD. Journal of Clinical Psychopharmacology, 19, 381–382. PubMed

Howard, A. K., Thornton, A. E., Altman, S., & Honer, W. G. (2002). Donepezil for memory dysfunction in schizophrenia. Journal of Psychopharmacology, 16, 267–270. PubMed

Kahng, S., Iwata, B. A., & Lewin, A. B. (2002). The impact of functional assessment on the treatment of self-injurious behavior. In S. R. Schroeder, M. L. Oster-Granite, & T. L. Thompson (Eds.), Self-injurious behavior: Gene–brain-behavior relationships (pp. 119–131). Washington, DC: American Psychological Association

Kandel, E. R. (2001). The molecular biology of memory storage: A dialogue between genes and synapses. Science, 294, 1030–1038. PubMed

Kaye, N. S., Townsend, J. B., & Ivins, R. (2003). An open-label trial of donepezil (Aricept) in the treatment of persons with mild traumatic brain injury. Journal of Neuropsychiatry and Clinical Neuroscience, 15, 383–384.

Khateb, A., Ammann, J., Annoni, J. M., & Diserens, K. (2005). Cognition-enhancing effects of donepezil in traumatic brain injury. European Neurology, 54, 39–45. PubMed

Kishnani, P. S., Sullivan, J. A., Walter, B. K., Spiridigliozzi, G., Doraiswamy, P. M., & Krishnan, K. R. R. (1999). Cholinergic therapy for Down’s syndrome. Lancet, 353, 1064–1065. PubMed

Kondoh, T., Amamoto, N., Doi, T., Hamada, H., Ogawa, Y., Nakashima, M., et al. (2005). Dramatic improvement in Down syndrome–associated cognitive impairment with donepezil. Annals of Pharmacotherapy, 39, 563–566. PubMed

Kosasa, T., Kuriya, Y., Matsui, K., & Yamanishi, Y. (1999). Inhibitory effects of donepezil hydrochloride (E2020) on cholinesterase activity in brain and peripheral tissues of young and aged rats. European Journal of Pharmacology, 10, 7–13.

Krnjevic, K., & Reinhardt, W. (1979). Choline excites cortical neurons. Science, 206, 1321–1323. PubMed

Lee, M., Martin-Ruiz, C., Graham, A., Court, J., Jaros, E., Perry, R., et al. (2002). Nicotinic receptor abnormalities in the cerebellar cortex in autism. Brain, 125, 1483–1495. PubMed

Levin, E. D. (1992). Nicotinic systems and cognitive function. Psychopharmacology, 108, 417–431. PubMed

Levin, E. D. (2000). The role of nicotinic acetylcholine receptors in cognitive function. In F. Clementi, D. Fornasari, & C. Gotti (Eds.), Neuronal nicotinic receptors: Experimental pharmacology (pp. 587–602). Berlin: Springer.

Levin, E. D., Conners, C., Sparrow, E., Hinton, S., Erhardt, D., & Meck, W., et al. (1996). Nicotine effects on adults with attention deficit hyperactivity disorder. Psychopharmacology, 123, 55–63. PubMed

Levin, E. D., Lee, C., Rose, J. E., Reyes, A., Ellison, G., Jarvik, M., & Gritz, E. (1990). Chronic nicotine and withdrawal effects on radial arm maze performance in rats. Behavioral and Neural Biology, 53, 269–276. PubMed

Levin, E. D., & Torry, D. (1996). Acute and chronic nicotine effects of working memory in aged rats. Psychopharmacology, 123, 217–230.

Lindsay, R. L., & Aman, M. M. (2003). Pharmacologic therapies aid treatment for autism. Pediatric Annals, 32, 671–676. PubMed

Lott, I. T., Osann, K., Doran, E., & Nelson, L. (2002). Down syndrome and Alzheimer disease, response to donepezil. Archives of Neurology, 59, 1133–1136. PubMed

Luine, V. N., Mohan, G., Tu, Z., & Efange, S. M. N. (2002). Chromaproline and chromaperidine, nicotine agonists, and donepezil cholinesterase inhibitor, enhance performance of memory tasks in ovariectomized rats. Pharmacology, Biochemistry, and Behavior, 74, 213–220. PubMed

MacEwan, G. W., Ehmann, T. S., Khanbhai, I., & Wrixon, C. (2001). Donepezil in schizophrenia – is it helpful? An experimental design case study. Acta Psychiatrica Scandinavica, 104, 469–471. PubMed

Mann, E. M. A. (1988). Alzheimer’s disease and Down’s syndrome. Histopathology, 13, 125–137. PubMed

Mann, E. M. A., & Esiri, M. M. (1989). The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down’s syndrome. Journal of the Neurological Sciences, 89, 169–179. PubMed

Masanic, C. A., Bayley, M. T., van Reekum, R., & Simard, M. (2001). Open-label study of donepezil in traumatic brain injury. Archives of Physical Medicine and Rehabilitation, 82, 896–901. PubMed

McCracken, J. T., McGough, J., Shah, B, Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., McDougle, C. J., Posey, D., Swiezy, N., Kohn, A., Scahill, L., Martin, A., Koenig, K., Volkmar, F., Carroll, D., Lancor, A., Tierney, E., Ghuman, J., Gonzalez, N. M., Grados, M., Vitiello, B., Ritz, L., Davies, M., Robinson, J., & McMahon, D. (Research Units on Pediatric Psychopharmacology Autism Network). (2002). Risperidone in children with autism and serious behavioral problems. New England Journal of Medicine, 347, 314–321. PubMed

McDonald, M. P., & Overmeier, J. B. (1998). Present imperfect: A critical review of animal models of the mnemonic impairments in Alzheimer’s disease. Neuroscience & Biobehavioral Reviews, 22, 99–120.

McEachin, J. J., Smith, T., & Lovaas, O. I. (1993). Long-term outcome for children with autism who received early intensive behavioral treatment. American Journal on Mental Retardation, 97, 359–72. PubMed

Meyer, J. S., Chowdhury, M. H., Xu, G., Li, Y., & Wuach, M. (2002). Donepezil treatment of vascular dementia. Annals of the New York Academy of Sciences, 977, 482–486. PubMed

Mirza, N. R., & Stolerman, I. P. (2000). The role of nicotinic and muscarinic acetylcholine receptors in attention. Psychopharmacologia, 148, 243–250.

Morey, C. E., Cilo, M., Berry, J., & Cusik, C. (2003). The effect of Aricept® in persons with persistent memory disorder following traumatic brain injury: A pilot study. Brain Injury, 17, 809–815. PubMed

Mori, S. (2002). Response to donepezil in Alzheimer’s disease and Parkinson’s disease. Annals of the New York Academy of Sciences, 977, 493–500. PubMedCrossRef

Myhrer, T. (2003). Neurotransmitter systems involved in learning and memory in the rat: A meta-analysis based on studies of four behavioral tasks. Brain research. Brain research reviews, 41, 268–287. PubMed

Nahas, Z., George, M. S., Horner, M. D., Markowitz, J. S., Li, X., & Lorberbaum, J. P., et al. (2003). Augmenting atypical antipsychotics with a cognitive enhancer (donepezil) improves regional brain activity in schizophrenia patients: A pilot double-blind placebo controlled BOLD fMRI study. Neurocase, 9, 274–282. PubMed

Narahashi, T., Moriguchi, S., Zhao, X., Marszalec, W., & Yeh, J. Z. (2004). Mechanisms of action of cognitive enhancers on neuroreceptors. Biological & Pharmaceutical Bulletin, 27, 1701–1706. PubMed

National Institute of Mental Health, CGI (Clinical Global Impression) scale. (1985). Psychopharmacology Bulletin, 21, 839–843.

Niederhofer, H., Staffen, W., & Mair, A. (2002). Galantamine may be effective in treating autistic disorder. British Journal of Medicine, 325, 1422.

Newhouse, P. A., Potter, A., Corwin, J., & Lenox, R. (1992). Acute nicotinic blockade produces cognitive impairment in normal humans. Psychopharmacology, 108, 480–484. PubMed

Nicolodi, M., Galeotti, N., Ghelardini, C., Cartolini, A., & Sicuteri, F. (2002). Central cholinergic challenging of migraine by testing second-generation anticholinesterase drugs. Headache, 42, 596–602. PubMed

Nordberg, A. (2001). Nicotinic receptor abnormalities of Alzheimer’s disease: Therapeutic implications. Biological Psychiatry, 49, 200–210. PubMed

Owley, T., McMahon, W., Cook, E. H., Laulhere, T., South, M., & Mays, L. Z., et al. (2001). Multisite, double-blind, placebo-controlled trial of porcine secretin in autism. Journal of the American Academy of Child and Adolescent Psychiatry, 40, 1293–1299. PubMed

Owley, T., Steele, E., Corsello, C., Risi, S., McKaig, K., & Lord, C., et al. (1999). A double-blind, placebo-controlled trial of secretin for the treatment of autistic disorder. Medscape General Medicine, October, E2.

Paterson, D., & Nordberg, A. (2000). Neuronal nicotinic receptors in the human brain. Progress in Neurobiology, 61, 71–111.

Perry, E. K., Lee, M. L. W., Martin-Ruiz, C. M., Court, J. A., Volsen, S. G., & Merrit, J., et al. (2001). Cholinergic activities in autism, Abnormalities in the cerebral cortex and basal forebrain. American Journal of Psychiatry, 158, 1058–1066. PubMed

Perry, E. K., Tomlinson, B. E., Blessed, G., Bergmann, K., Gibson, P. H., Perry, R. H. (1978). Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. British Medical Journal, 2, 1457–1459. PubMedCrossRef

Prasher, V. P., Adams, C., Holder, R., & Down Syndrome Research Group. (2003). Long term safety and efficacy of donepezil in the treatment of dementia in Alzheimer’s disease in adults with Down syndrome, Open label study. International Journal of Geriatric Psychiatry, 18, 549–551. PubMed

Prasher, V. P., Huxley, A., & Haque, M. S. (2002). The Down syndrome ageing study group, A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer’s disease – pilot study. International Journal of Geriatric Psychiatry, 17, 270–278. PubMed

Pratt, R. D., Perdomo, C. A., Surick, I. W., & Ieni, J. R. (2002). Donepezil, tolerability and safety in Alzheimer’s disease. International Journal Clinical Practice, 56, 710–717.

Pratt, R. D., & Perdomo, C. A., & The donepezil VaD 307 and 308 study groups. (2002). Donepezil-treated patients with probable vascular dementia demonstrate cognitive benefits. Annals of the New York Academy of Sciences, 977, 513–522.

Prickaerts, J., Şık, A., van der Staay, F. J., de Vente, J., & Blokland, A. (2005). Dissociable effects of acetylcholinesterase inhibitors and phosphodiesterase type 5 inhibitors on object recognition memory: Acquisition versus consolidation. Psychopharmacology, 177, 381–390. PubMed

Reed, P., & Gibson, E. (2005). The effect of concurrent task load on stimulus over-selectivity. Journal of Autism Developmental Disorders, 35, 601–614.

Risch, S. C., McGurk, S., Horner, M. D., Nahas, Z., Owens, S. D., & Molloy, M., et al. (2001). A double-blind pacebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient, Functional MRI correlates. Neurocase, 7, 105–110. PubMed

Rogers, S. L., Doody, R. S., Mohs, R. C., Friedhoff, L. T., & The donepezil study group. (1998a). Donepezil improves cognition and global function in Alzheimer disease. Archives of Internal Medicine, 158, 1021–1031.

Rogers, S. L., Farlow, M. R., Doody, R. S., Mohs, R. C., Friedhoff, L. T., & The donepezil study group. (1998b). A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Neurology, 50, 136–145.

Rogers, S. L., & Friedhoff, L. T. (1998). Long-term efficacy and safety of donepezil in the treatment of Alzheimer’s disease: An interim analysis of the results of a US multicenter open label extension study. European Neuropsychopharmacology, 8, 67–75. PubMed

Rogers, S. L., Friedhoff, L. T., & The donepezil study group. (1996). The efficacy and safety of donepezil in patients with Alzheimer’s disease: Results of a US multicenter, randomized, double-blind, placebo-controlled trial. Dementia, 7, 293–303. PubMed

Rogers, S. L., Yamanishi, Y., & Yamatsu, K. (1991). E2020-The pharmacology of a piperidine cholinesterase inhibitor. In R. Becker & E. Giacobini (Eds.), Cholinergic basis for Alzheimer therapy (pp. 314–320). Boston: Birkhauser.

Rosenthal, R. (1991). Meta-analysis: A review. Psychosomatic Medicine, 53, 247–271. PubMed

Rosenzweig, M. R., & Bennett, E. L. (1996). Psychobiology of plasticity. Effects of training and experience on brain and behavior. Behavioural Brain Research, 78, 57–65. PubMed

Rupniak, N. M. J., Tye, S. J., & Field, M. J. (1997). Enhanced performance of spatial and visual recognition memory tasks by the selective acetylcholinesterase inhibitor E2020 in rhesus monkeys. Psychopharmacology, 131, 406–410. PubMed

Rusted, J., Graupner, L., O’Connell, N., & Nicholls, C. (1994). Does nicotine improve cognitive function? Psychopharmacology, 115, 547–549. PubMed

Sarter, M., & Bruno, J. P. (1999). Abnormal regulation of corticopetal cholinergic neurons and impaired information processing in neuropsychiatric disorders. Trends in Neuroscience, 22, 67–74.

Schupf, N., Kapell, D., Nightingale, B., Rodriguez, A., Tycko, B., & Mayeux, R. (1998). Earlier onset of Alzheimer’s disease in men with Down syndrome. Neurology, 40, 991–995.

Seltzer, B., Zolnouni, P., Nunez, M., Goldman R, Kumar, D., & Ieni, J., et al. (2004). Efficacy of donepezil in early-stage Alzheimer disease: A randomized placebo-controlled trial. Archives of Neurology, 61, 1852–1856. PubMed

Smith, T., Eikeseth, S., Klevstrand, M., & Lovaas, O. I. (1997). Intensive behavioral treatment for preschoolers with severe mental retardation and pervasive developmental disorder. American Journal on Mental Retardation, 102, 238–249. PubMed

Smith, T. (1999). Outcome of early intervention for children with autism. Clinical Psychology: Science and Practice, 6, 33–49.

Sokol, D. K., Dunn, D. W., Edwards-Brown, M., & Feinberg, J. (2002). Hydrogen proton magnetic resonance spectroscopy in autism: Preliminary evidence of elevated choline/creatine ratio. Journal of Child Neurology, 17, 245–249. PubMed

Spowart-Manning, L., & van der Staay, F. J. (2004). The T-maze continuous alternation task for assessing the effects of putative cognition enhancers in the mouse. Behavioural Brain Research, 151, 37–46. PubMed

Spowart-Manning, L., & van der Staay, F. J. (2005). Spatial discrimination deficits by excitotoxic lesions in the Morris water escape task. Behavioural Brain Research, 156, 269–276. PubMed

Stahl, S. M. (2000). Essential psychopharmacology: Neuroscientific basis and practical applications. New York: Cambridge University Press.

Stryjer, R., Strous, R., Bar, F., Werber, E., Shaked, G., & Buhiri, Y., et al. (2003). Beneficial effect of donepezil augmentation for the management of comorbid schizophrenia and dementia. Clinical Neuropharmacology, 26, 12–17. PubMed

Sugimoto, H. (2001). Donepezil hydrochloride, a treatment drug for Alzheimer’s disease. Chemical Reactions, 1, 63–73.

Takahata, K., Minami, A., Kusumoto, H., Shimazu, S., & Yoneda, F. (2005). Effects of selegiline alone or with donepezil on memory impairment in rats. European Journal of Pharmacology, 518, 140–144. PubMed

Taverni, J. P., Seliger, G., & Lichtman, S. W. (1998). Donepezil medicated memory improvement in traumatic brain injury during post acute rehabilitation. Brain Injury, 12, 77–80. PubMed

Tenovuo, O. (2005). Central acetylcholinesterase inhibitors in the treatment of chronic traumatic brain injury – clinical experience in 111 patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 29, 61–67. PubMed

Tokita, K., Yamazaki, S., Yamazaki, M., Matsuoka, N., & Mutoh, S. (2002). Combination of a novel antidementia drug FK 960 with donepezil synergistically improves memory deficits in rats. Pharmacology, Biochemistry, and Behavior, 73, 511–519. PubMed

Tsai, L. Y. (1999). Pharmacology in autism. Psychosomatic Medicine, 61, 651–665. PubMed

Tsukada, H., Nishiyama, S., Fukumoto, D., Ohba, H., Sata, K., & Kakiuchi, T. (2004). Effects of acute acetylcholinesterase inhibition on the cerebral cholinergic neuronal system and cognitive function: Functional imaging of the conscious monkey brain using animal PET in combination with microdialysis. Synapse, 52, 1–10. PubMed

Tuğal, Ö., Yazıcı, K. M., Yağcıoğlu, A. E. A., & Göğüş, A. (2004). A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia. International Journal of Neuropsychopharmacology, 7, 117–123. PubMed

Van Dam, D., Abramowski, D., Staufenbiel, M., & De Deyn, P. P. (2005). Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model. Psychopharmacology, 180, 177–190. PubMed

Van Reekum, R., Black, S.E., Conn, D., & Clarke, D. (1997). Cognition-enhancing drugs in dementia: A guide to the near future. Canadian Journal of Psychiatry, 42, 35S–50S.

Walker, W., Seel, R., Gibellato, M., Lew, H., Cornis-Pop, M, & Jena, T., et al. (2004). The effects of donepezil on traumatic brain injury acute rehabilitation outcomes. Brain Injury, 18, 739–750. PubMed

Whelan, F. J., Walker, M. S., & Schultz, S. K. (2000). Donepezil in the treatment of cognitive dysfunction associated with traumatic brain injury. Annals of Clinical Psychiatry, 12, 131–135. PubMed

White, K. G., & Ruske, A. C. (2002). Memory deficits in Alzheimer’s disease: The encoding hypothesis and cholinergic function. Psychonomic Bulletin & Review, 9, 426–437.

Whitehead, A., Perdomo, C., Pratt, R. D., Birks, J., Wilcock, G. K., & Evans, J. G. (2004). Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer’s disease: A meta-analysis of individual patient data from randomised controlled trials. International Journal of Geriatric Psychiatry, 19, 624–633. PubMed

Whitlock, J. (1999). Brain injury, cognitive impairment, and donepezil. Journal of Head Trauma Rehabilitation, 14, 424–427. PubMed

Wilens, T. E., Biederman, J., Wong, J., Spencer, T. J., & Prince, J. B. (2000). Adjunctive donepezil in attention deficit hyperactivity disorder youth: Case series. Journal of Child and Adolescent Psychopharmacology, 10, 217–222. PubMed

Williams, D. C., & Saunders, K. J. (1997). Methodological issues in the study of drug effects on cognitive skills in mental retardation. International Review of Research in Mental Retardation, 21, 147–185. CrossRef

Zhang, L., Plotkin, R. C., Wang, G., Sandel, E., & Lee, S. (2004). Cholinergic augmentation with donepezil enhances recovery in short-term memory and sustained attention after traumatic brain injury. Archives of Physical Medicine and Rehabilitation, 85, 1050–1055. PubMed

Zhang, L., Zhou, F. M., & Dani, J. A. (2004). Cholinergic drugs for Alzheimer’s disease enhance in vitro dopamine release. Molecular Pharmacology, 66, 538–544. PubMed

Zigman, W. B., Schupf, N., Devenny, D. A., Miezejeski, C., Ryan, R., & Urv, T. K., et al. (1995). Incidence and prevalence of dementia in adults with and without Down syndrome. American Journal on Mental Retardation, 100, 403–412.

Titel: Relevance of Donepezil in Enhancing Learning and Memory in Special Populations: A Review of the Literature
Auteurs: J. Helen Yoo
Maria G. Valdovinos
Dean C. Williams
Publicatiedatum: 01-11-2007
Uitgeverij: Springer US
Gepubliceerd in: Journal of Autism and Developmental Disorders / Uitgave 10/2007
Print ISSN: 0162-3257
Elektronisch ISSN: 1573-3432
DOI: https://doi.org/10.1007/s10803-006-0322-8

Bohn Stafleu van Loghum

Tip

Swipe om te navigeren naar een ander artikel

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Log in om toegang te krijgen

Andere artikelen Uitgave 10/2007

The Impact of Meaning and Dimensionality on Copying Accuracy in Individuals with Autism

Eating and Drinking Difficulties in Children: A Guide for Practitioners

Asperger (1906–1980) and Kanner (1894–1981), the two pioneers of autism

Trends in Special Education Code Assignment for Autism: Implications for Prevalence Estimates

Treating Anxiety Disorders in Children with High Functioning Autism Spectrum Disorders: A Controlled Trial

Factor Analysis of the Aberrant Behavior Checklist in Individuals with Autism Spectrum Disorders